Related Experiment Video
Updated: Apr 6, 2026
Biomolecular Imaging of Cellular Uptake of Nanoparticles using Multimodal Nonlinear Optical Microscopy
Published on: May 16, 2022
A multimodal nano agent for image-guided cancer surgery
Jinzi Zheng1, Nidal Muhanna2, Raquel De Souza3
1Techna Institute, University Health Network, 100 College Street, Toronto, Ontario, M5G 1P5, Canada; Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada; University of Toronto, Institute of Biomaterials and Biomedical Engineering, 164 College Street, Rm 407, Toronto, Ontario, M5S 3G9, Canada.
A novel dual-modality nano liposomal agent (CF800) enhances cancer surgery by improving computed tomography and near-infrared fluorescence imaging. This agent aids in surgical planning and intraoperative guidance, leading to better tumor visualization and resection.
Area of Science:
- Oncology
- Medical Imaging
- Nanotechnology
Background:
- Intraoperative imaging, including computed tomography (CT) and fluorescence optical imaging, is crucial for effective cancer surgery.
- Enhancing these techniques with novel contrast agents can improve surgical precision and patient outcomes.
- Developing agents that combine multiple imaging modalities offers synergistic benefits for complex cancer resections.
Purpose of the Study:
- To develop and evaluate a dual-modality nano liposomal agent (CF800) for computed tomography (CT) and near-infrared (NIR) fluorescence imaging in cancer surgery.
- To assess the agent's efficacy in preoperative surgical planning and intraoperative tumor visualization and resection.
- To determine the potential of CF800 to improve lesion localization, margin delineation, and metastatic lymph node detection.
Main Methods:
- Development of a dual-modality nano liposomal agent (CF800) integrating CT contrast and NIR fluorescence properties.
- Preclinical testing in multiple animal cancer models to evaluate detection and visualization capabilities.
- Application for CT-based 3D surgical planning and intraoperative NIR fluorescence-guided resection.
Main Results:
- CF800 demonstrated significant CT enhancement (>200 Hounsfield Units) for preoperative planning and intraoperative mapping.
- The agent achieved a substantial tumor-to-background ratio (>5-fold) in NIR fluorescence imaging for guided resection.
- Successful visualization and targeting of cancerous tissues were achieved in preclinical models.
Conclusions:
- The developed dual-modality agent (CF800) shows significant promise for image-guided cancer surgery.
- CF800 can enhance both CT-based planning and fluorescence-guided resection, improving surgical accuracy.
- Further clinical advancement of this agent could lead to improved patient outcomes in cancer treatment.
